BR112021024507A2 - Agonista de pd-1 e método de uso do mesmo - Google Patents

Agonista de pd-1 e método de uso do mesmo

Info

Publication number
BR112021024507A2
BR112021024507A2 BR112021024507A BR112021024507A BR112021024507A2 BR 112021024507 A2 BR112021024507 A2 BR 112021024507A2 BR 112021024507 A BR112021024507 A BR 112021024507A BR 112021024507 A BR112021024507 A BR 112021024507A BR 112021024507 A2 BR112021024507 A2 BR 112021024507A2
Authority
BR
Brazil
Prior art keywords
agonist
chain polypeptide
production
methods
well
Prior art date
Application number
BR112021024507A
Other languages
English (en)
Inventor
N Gold Gregory
Janean Fisher
Habash Marino Margaret
Marilyn Kehry
Edward Dahl Martin
P Morse Robert
Rupal Kalapanda
Stephen Parmley
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of BR112021024507A2 publication Critical patent/BR112021024507A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

agonista de pd-1 e método de uso do mesmo. é fornecido um agente de ligação a pd-1 que compreende um polipeptídeo da cadeia pesada de imunoglobulina e polipeptídeo da cadeia leve de imunoglobulina, bem como composições e métodos relacionados para sua produção e utilização.
BR112021024507A 2019-06-05 2020-06-04 Agonista de pd-1 e método de uso do mesmo BR112021024507A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962857699P 2019-06-05 2019-06-05
US201962863193P 2019-06-18 2019-06-18
US202062983512P 2020-02-28 2020-02-28
PCT/US2020/036143 WO2020247648A2 (en) 2019-06-05 2020-06-04 Pd-1 agonist and method of using same

Publications (1)

Publication Number Publication Date
BR112021024507A2 true BR112021024507A2 (pt) 2022-03-08

Family

ID=71895175

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024507A BR112021024507A2 (pt) 2019-06-05 2020-06-04 Agonista de pd-1 e método de uso do mesmo

Country Status (12)

Country Link
US (1) US20220235132A1 (pt)
EP (1) EP3980460A2 (pt)
JP (1) JP7490679B2 (pt)
KR (1) KR20220016925A (pt)
CN (1) CN114364697A (pt)
AU (1) AU2020286444A1 (pt)
BR (1) BR112021024507A2 (pt)
CA (1) CA3142714A1 (pt)
IL (1) IL288361A (pt)
MX (1) MX2021015054A (pt)
TW (1) TW202112815A (pt)
WO (1) WO2020247648A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115956087A (zh) 2020-05-26 2023-04-11 勃林格殷格翰国际有限公司 抗-pd-1抗体
KR20240007203A (ko) 2021-05-13 2024-01-16 고에키 자이단 호징 고베 이료 산교 도시 스이신 기코 염증성 질환을 치료 또는 예방하기 위한 항-인간 pd-1 작용제 항체 및 이를 함유하는 의약 조성물
IL312215A (en) * 2021-11-19 2024-06-01 Mirobio Ltd PD-1 antibodies and their uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
EP1576014B1 (en) * 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
US20090075378A1 (en) 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies

Also Published As

Publication number Publication date
US20220235132A1 (en) 2022-07-28
MX2021015054A (es) 2022-03-17
KR20220016925A (ko) 2022-02-10
EP3980460A2 (en) 2022-04-13
CA3142714A1 (en) 2020-12-10
TW202112815A (zh) 2021-04-01
JP7490679B2 (ja) 2024-05-27
IL288361A (en) 2022-01-01
CN114364697A (zh) 2022-04-15
WO2020247648A3 (en) 2021-01-14
AU2020286444A1 (en) 2021-12-23
WO2020247648A2 (en) 2020-12-10
JP2022534803A (ja) 2022-08-03

Similar Documents

Publication Publication Date Title
BR112021024507A2 (pt) Agonista de pd-1 e método de uso do mesmo
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CL2017002401A1 (es) Anticuerpos contra icos
CL2023001092A1 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
NI201800055A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos.
PE20211412A1 (es) Anticuerpos anti-gdf15, composiciones y metodos de uso
ECSP19058592A (es) Polipéptidos de unión al receptor de transferrina diseñados
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CO2018003973A2 (es) Proteínas de unión a pd-1 y métodos para usarlas
CL2019001646A1 (es) Anticuerpos anti-ox40 y sus usos.
CL2021002586A1 (es) Anticuerpos de cadena pesada que se unen al psma
AR124692A2 (es) Anticuerpos anti-cd40 y sus usos
CO2022008407A2 (es) Anticuerpos específicos para cd47, pd–l1 y sus usos
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
ECSP21090414A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CL2019002792A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo.
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CO2017000416A2 (es) Una composición hidráulica
AR117565A1 (es) Agentes de unión a c3 y método de uso de los mismos
PE20220297A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos
CO2020006453A2 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
BR112019003771A2 (pt) método para fabricar um componente de combustível
CO6721048A2 (es) Anticuerpos que se unen a notum pectinacetilesterasa
AR111752A1 (es) Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos
CO2019009035A2 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas